Daniela Guerrera

Istituto di Biomedicina e di Immunologia Molecolare Alberto Monroy

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

G Bonsignore

University of Palermo

Mirella Profita

Istituto di Biomedicina e di Immunologia Molecolare Alberto Monroy

Mario Traina

Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione

Giovanni Vizzini

Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione

Loredana Riccobono

Istituto di Biomedicina e di Immunologia Molecolare Alberto Monroy

Linda Pasta

Ospedale Vincenzo Cervello

Gennaro D’Amico

Ospedale Vincenzo Cervello

F. Politi

Hospital Sírio-Libanês

A M Vignola

Université de Sherbrooke

Antonio M. Vignola

University of Palermo

Cooperative Institutions

University of Palermo

Ospedale Vincenzo Cervello

Istituto di Biomedicina e di Immunologia Molecolare Alberto Monroy

National Research Council

National Academies of Sciences, Engineering, and Medicine

Institute for Biomedical Research and Innovation

University of Milan

Istituto di Farmacologia Traslazionale

Hospital Universitário Onofre Lopes

National Research Council

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Octreotide Compared With Placebo in A Treatment Strategy for Early Rebleeding in Cirrhosis. A Double Blind, Randomized Pragmatic Trial

Hepatology (1998)

Gennaro D’Amico F. Politi Alberto Morabito Adele D’Antoni Daniela Guerrera

β–Blockers and sclerotherapy prevent long–term upper digestive rebleeding in cirrhosis but they seem ineffective for early rebleeding. We compared octreotide with a placebo for the prevention of early rebleeding in cirrhotic patients. After control of acute upper digestive bleeding, 262 consecutive cirrhotic patients were randomized to octreotide 100 μg subcutaneously three times a day for 15 days (n = 131) or to the placebo (n = 131), in a double blind pragmatic trial in which β–blockers and/or sclerotherapy were allowed together with the experimental treatment. Separate randomization and analysis were performed according to whether patients were eligible for β–blockers and/or sclerotherapy (101 placebo, 97 octreotide) or not (30 placebo, 34 octreotide). Rebleeding within 15 days was the primary measure of treatment efficacy; 6–week rebleeding rate was also assessed as a secondary measure. Fifteen–day cumulative proportions of patients rebleeding were 28% in the placebo group and 24% in the octreotide group ( P = .40); corresponding figures among the 198 patients eligible to β–blockers and/or sclerotherapy were 26% and 16% ( P = .05) and among the 64 not eligible for these treatments 33% and 49% ( P = .29). Among patients eligible to β–blockers and/or sclerotherapy, a significant reduction of rebleeding episodes (35 vs. 18, P = .03), blood transfusions (75 vs. 50, P = .04), and days of stay in hospital (1,544 vs. 1,190, P = .0001) was also found in the octreotide group: this beneficial effect was confirmed 6 weeks after randomization. Mortality was not affected by octreotide in either group of patients. It is suggested that octreotide may reduce the risk of early rebleeding in cirrhotic patients treated with β–blockers and/or sclerotherapy after control of acute upper digestive bleeding. Further studies are needed to confirm this result.

10.1002/hep.510280507

Cite

Citations (78)

Lung Function Decline in Bronchial Asthma

CHEST Journal (2002)

Fabio Cibella Giuseppina Cuttitta Vincenzo Bellia Salvatore Bucchieri Silvestre D’Anna

10.1378/chest.122.6.1944

Cite

Citations (35)

Are asthma and chronic bronchitis different diseases? Pro.

PubMed (1999)

A M Vignola Rosalia Gagliardo Daniela Guerrera Liboria Siena Pascal Chanez

Chronic bronchitis

Source

Cite

Citations (2)

15-Lipoxygenase expression and 15(S)-hydroxyeicoisatetraenoic acid release and reincorporation in induced sputum of asthmatic subjects

Journal of Allergy and Clinical Immunology (2000)

Mirella Profita Angelo Sala Loredana Riccobono Alessandra Paternò A Mirabella

Cell type

10.1067/mai.2000.105122

Cite

Citations (54)

Effects of low doses of inhaled fluticasone propionate on inflammation and remodelling in persistent‐mild asthma

Allergy (2005)

A M Vignola Loredana Riccobono Mirella Profita Antonio Foresi R. Di Giorgi

In asthma a dysregulation of eosinophil apoptosis and an imbalance of metalloproteinase‐9 (MMP‐9) and tissue inhibitor metalloproteinase‐1 (TIMP‐1) play an important role in airway inflammation and remodelling. We evaluated the effects of a low dose of inhaled fluticasone proprionate (FP) (100 μ g bid by Diskus) for 4 weeks in 24 steroid naive patients with mild persistent asthma, symptomatic and with a sputum eosinophilia ≥3% on clinical outcomes and inflammatory markers such as the induced sputum eosinophils, the induced sputum apoptotic eosinophils, the levels of MMP‐9 and TIMP‐1 and their molar ratio in the induced sputum supernatants. After FP treatment forced expiratory volume (FEV1) and FEV1/forced vital capacity values, PEF (L/min), sputum apoptotic eosinophils, and MMP‐9/TIMP‐1 molar ratio in sputum supernatants of asthmatic subjects were significantly increased in comparison with baseline, while sputum eosinophils significantly decreased. Change (Δ) in FEV1 after treatment with FP negatively correlated with the Δ in sputum eosinophils, while the Δ in MMP‐9 values positively correlated with Δ in TIMP‐1 values. This study shows that the clinical improvement achieved by the use of low doses of FP in asthmatics is related, at least in part, to the resolution of eosinophilic inflammation and the downregulation of remodelling markers.

Fluticasone propionate

Fluticasone

10.1111/j.1398-9995.2005.00827.x

Cite

Citations (22)

Natural history of cirrhosis

Journal of Hepatology (1991)

Gennaro D’Amico Linda Pasta Giovanni Vizzini F. Politi Mario Traina

10.1016/0168-8278(91)91075-r

Cite

Citations (11)